Cancer
Commented by André Will-Laudien on October 8th, 2025 | 07:30 CEST
BioNxt Solutions – A small biotech gem with huge potential
Modern medicine is undergoing a paradigm shift - and BioNxt Solutions could emerge as one of its key pioneers. The German-Canadian biotech company is developing innovative drug delivery platforms designed to make existing medications more effective, safer, and more patient-friendly. Whether for obesity, multiple sclerosis, or cancer, BioNxt is targeting several multi-billion-dollar markets with disruptive potential. Backed by patented technologies and an agile development strategy, BioNxt is laying the foundation for above-average growth and attractive licensing models. For investors, this could be a rare chance to get in early on what could be the next big thing in healthcare innovation.
Read
Commented by Armin Schulz on October 7th, 2025 | 07:20 CEST
Cancer research with billion-dollar potential: How Bayer, Vidac Pharma, and BioNTech could come into play
The oncology market is booming like no other. Driven by technological quantum leaps and, unfortunately, rising case numbers, cancer treatment is becoming a highly lucrative innovation engine. The sector is growing at double-digit rates every year. Experts predict that the global market volume will break the USD 1 trillion mark within the next decade. No wonder, then, that the race for the next therapeutic breakthroughs in personalized medicines and AI-supported active ingredients is heating up. Investors are focusing not only on established players like Bayer, but also on up-and-coming specialists such as Vidac Pharma and mRNA pioneers like BioNTech.
Read
Commented by Nico Popp on September 18th, 2025 | 07:05 CEST
Understanding metabolism, generating returns: Vidac Pharma, Roche, AstraZeneca
In the search for new treatments against diseases, researchers agree on one thing: the holy grail is unlikely to be found. Instead, it is incremental improvements and combination therapies that promise progress in complex diseases such as cancer. Cell metabolism is considered a promising approach, for example, in cancer, when the metabolism of a cancer cell is disrupted, the cell dies. In this article, we present current approaches and also discuss a biotechnology company that is wholly dedicated to cellular metabolism.
Read
Commented by Nico Popp on August 25th, 2025 | 07:05 CEST
New research findings – Cell metabolism relevant in cancer: Roche, Novartis, and Vidac Pharma
What if cancer cells no longer grew uncontrollably, and we could target the metabolism of these cells directly? The so-called Warburg effect makes this possible. Discovered around 100 years ago by Otto Warburg, the effect describes the energy metabolism of cancer cells and shows that their metabolism differs from that of healthy cells. This opens up great opportunities for specific therapies in biotechnology. The theoretical assumption is that if the metabolism of cancer cells can be specifically disrupted, treatment will be targeted and free of side effects. Biotech start-up Vidac Pharma is fully committed to the Warburg effect. We explain what the Canadians are researching and why the technology could complement the offerings of several large pharmaceutical companies.
Read
Commented by Armin Schulz on July 28th, 2025 | 07:00 CEST
War, raw material shortages, cancer: Capitalize on megatrends with Rheinmetall, Antimony Resources, Merck KGaA
Three megatrends are expected to drive global markets in 2025. Revolutionary technologies, such as AI and cybersecurity, are fundamentally changing the defence sector. At the same time, demand for critical raw materials for defense, high-tech applications, and the energy transition is exploding, requiring new, sustainable supply chains. In parallel, the pharmaceutical industry is undergoing a dramatic shift due to advances in AI-driven research and intensified competition. These forces are shaping the future opportunities for companies. Those who are strategically positioned here will win, as key players Rheinmetall, Antimony Resources, and Merck KGaA demonstrate.
Read
Commented by Nico Popp on July 25th, 2025 | 07:00 CEST
Key technology in the fight against cancer? Merck & Co., Vidac Pharma, AstraZeneca
Do you know what aerobic glycolysis is? No? Have you ever heard of the Warburg effect? Both terms describe the same phenomenon: cancer cells utilize glucose to produce lactate, even in the presence of oxygen and fully functional mitochondria. This is what distinguishes cancer cells from healthy cells. Current research suggests that targeted interventions in the Warburg effect could be suitable for killing cancer cells or making them more receptive to other therapies. Companies around the world are pushing forward research into this effect – the goal is nothing less than curing cancer. We present some of the companies and analyze whether their stocks could be good investments.
Read
Commented by Armin Schulz on May 6th, 2024 | 07:15 CEST
Bayer on the path out of crisis. With their oncology pipelines, are Defence Therapeutics and BioNTech also on the verge of a turnaround?
After several years of stumbling from one crisis to another, pharmaceutical and agrochemical giant Bayer is now showing signs of a recovery on the horizon. As Bayer navigates its long and rocky road out of the crisis, investors and industry experts are now turning their attention to two other exciting biotech companies: Defence Therapeutics and BioNTech. Both companies, which have caused a sensation in the past mainly due to their revolutionary approaches in cancer therapy, could follow in Bayer's footsteps with their promising oncology pipelines, moving from uncertainty to a bright future.
Read
Commented by Armin Schulz on April 30th, 2024 | 07:00 CEST
Evotec, Vidac Pharma, BioNTech - The billion-dollar race for cancer therapy
Oncology is on the brink of a golden era. Driven by an increase in cancer cases and impressive scientific advances, including gene and immunotherapies, a billion-dollar market with immense growth prospects is emerging. The increasing demand for personalized medicines and the rapid development of new forms of therapy through technological progress are driving revenues in the pharmaceutical industry. This not only underlines the enormous financial value of oncology as an investment area but also promises ground-breaking improvements in patient care. We look at three companies that could benefit from this.
Read
Commented by André Will-Laudien on April 24th, 2024 | 07:00 CEST
Takeover rumors for biotech shares: BioNTech, Formycon, Cardiol Therapeutics and Novo Nordisk in focus
The biotech sector has significantly lagged behind the performance of artificial intelligence and high-tech this year. This is due to high inflation, which in turn has made an imminent interest rate cut unlikely. Nevertheless, Germany's economic conditions are deteriorating dramatically, particularly due to the ongoing geopolitical conflicts. It should, therefore, come as no surprise if the ECB announces an "emergency interest rate cut" in the summer. That would then be the starting signal for a major reshuffle out of the best performers of recent months and into the long-neglected biotech segment. We have selected a few interesting stocks.
Read
Commented by Fabian Lorenz on April 23rd, 2024 | 07:00 CEST
TAKEOVER FEVER for biotech shares! Evotec, Bayer, Vidac Pharma - Who will follow Morphosys?
There is takeover fever in the biotech sector. Genmab recently announced the acquisition of ProfoundBio, the US biotech company developing ovarian and endometrial cancer drugs, for USD 1.8 billion. With Morphosys, the takeover carousel is also turning in Germany. Who is the next candidate? Evotec is often mentioned. Due to unauthorized insider trading, the biotech company's shares have come under fire this year and offer an interesting entry opportunity. Vidac Pharma also impresses operationally. The Company's new approach has the potential to revolutionize cancer treatment. The study results of the past few months are very promising. Bayer shares surprised investors yesterday as one of the day's winners in the DAX. Is the Leverkusen-based company's stock about to take off?
Read